The Immunomodulatory Effect of Antrifibrinolytic (Tranexamic Acid) in Total Knee Arthroplasty
NCT ID: NCT03795649
Last Updated: 2019-01-08
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
80 participants
Study Classification
INTERVENTIONAL
Study Start Date
2018-12-18
Study Completion Date
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The administration of the tranexamic acid (TRAXA), an antifibrinolytic, blocks primary fibrinolysis, and thus the haemorrhage, in the early postoperative period. Significant surgical operations, as well as trauma, initiate a similar dynamic homeostatic mechanism between the creation of a clot (primary and secondary haemostasis) and its dissolution (fibrinolysis). Antifibrinolytics have been proven effective in reducing haemorrhage in patients who have undergone significant surgical operations with normal fibrinolysis, with the use of an appropriate surgical technique.
A pharmacokinetic study has shown that peak fibrinolytic activity is present for 6 hours after the incision and it persists for 18 hours in total knee and hip arthroplasty. The administration of the tranexamic acid in optional orthopaedic surgery of total hip (THA) and knee (TKA) arthroplasty reduces the postoperative haemorrhage, as well as the number and volume of the postoperative autologous blood.
A trauma in the organism triggers the immunologic response. New term has been introduced - the post-traumatic immunosuppression (PTI), characterised by: a change on the immunologic cells (neutrophilia, monocytosis, increased number of mesenchymal stromal cells, reduced expression of HLA-DR on monocytes, reduced function of natural killer (NK) cells, increased lymphocyte apoptosis, a shift in homoeostasis towards the Th2 phenotype facilitated by Treg lymphocytes - CD4+CD25+CD127-); a change in production levels of various cytokines (anti-inflammatory cytokines): IL-10, IL-4; anti- and pro-inflammatory cytokine: IL-6; pro-inflammatory cytokines IL-2, TNF-α, IFN-γ); the activation of the complement system (C5a and C3a via factor VII - tissue factor system, activated by cell damage).
Post-traumatic immunosuppression can be made worse by transfusion, haemorrhage, stress, significant surgical operation and immunosuppressive drugs.
The research has shown that Treg lymphocytes CD4+CD25+CD127- have an important role in controlling the acquired and innate immunity (comprising 6-8% of all CD4+ lymphocytes).
Stopping haemorrhage prevents the occurrence of anaemia, as well as the need for transfusion of blood products, which lead to developing the post-traumatic immunosuppression (PTI).
A pharmacokinetic study has shown that peak fibrinolytic activity is present for 6 hours after the incision and it persists for 18 hours in total knee and hip arthroplasty. The administration of the tranexamic acid in optional orthopaedic surgery of total hip (THA) and knee (TKA) arthroplasty reduces the postoperative haemorrhage, as well as the number and volume of the postoperative autologous blood.
A trauma in the organism triggers the immunologic response. New term has been introduced - the post-traumatic immunosuppression (PTI), characterised by: a change on the immunologic cells (neutrophilia, monocytosis, increased number of mesenchymal stromal cells, reduced expression of HLA-DR on monocytes, reduced function of natural killer (NK) cells, increased lymphocyte apoptosis, a shift in homoeostasis towards the Th2 phenotype facilitated by Treg lymphocytes - CD4+CD25+CD127-); a change in production levels of various cytokines (anti-inflammatory cytokines): IL-10, IL-4; anti- and pro-inflammatory cytokine: IL-6; pro-inflammatory cytokines IL-2, TNF-α, IFN-γ); the activation of the complement system (C5a and C3a via factor VII - tissue factor system, activated by cell damage).
Post-traumatic immunosuppression can be made worse by transfusion, haemorrhage, stress, significant surgical operation and immunosuppressive drugs.
The research has shown that Treg lymphocytes CD4+CD25+CD127- have an important role in controlling the acquired and innate immunity (comprising 6-8% of all CD4+ lymphocytes).
Stopping haemorrhage prevents the occurrence of anaemia, as well as the need for transfusion of blood products, which lead to developing the post-traumatic immunosuppression (PTI).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study the Anti-inflammatory Effect of Tranexamic Acid When Used in Anterior Cruciate Ligament Reconstruction.
NCT07332910
ACL Reconstruction
Hemarthrosis
NOT_YET_RECRUITING
PHASE4
Tranexamic Acid for Unilateral Total Knee Arthroplasty
NCT01594671
Blood Loss
COMPLETED
PHASE3
Tranexamic Acid in Total Knee Replacement
NCT03656445
Osteo Arthritis Knee
COMPLETED
NA
Oral Administration of Tranexamic Acid in Anterior Cruciate Ligament Surgery Reduce Postoperative Haemarthrosis
NCT04855877
Hemorrhage Postoperative
Anterior Cruciate Ligament Rupture
Arthroscopy
+1 more
UNKNOWN
PHASE4
In Vivo Study of Local Tranexamic Acid Concentrations Following Intra-Articular Administration in Total Knee Arthroplasty
NCT06876181
Local Concentration of Tranexamic Acid Following Intra-articular Administration in TKA
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The administration of the tranexamic acid (TRAXA), an antifibrinolytic, blocks primary fibrinolysis, and thus the haemorrhage, in the early postoperative period. Significant surgical operations, as well as trauma, initiate a similar dynamic homeostatic mechanism between the creation of a clot (primary and secondary haemostasis) and its dissolution (fibrinolysis). Antifibrinolytics are initially used in patients with an accelerated fibrinolysis of different pathogeneses. However, they have been proven effective in reducing haemorrhage in patients who have undergone significant surgical operations with normal fibrinolysis, with the use of an appropriate surgical technique.
A pharmacokinetic study has shown that peak fibrinolytic activity is present for 6 hours after the incision and it persists for 18 hours in total knee and hip arthroplasty. The administration of the tranexamic acid in optional orthopaedic surgery of total hip (THA) and knee (TKA) arthroplasty reduces the postoperative haemorrhage, as well as the number and volume of the postoperative autologous blood.
A randomized, placebo-controlled trial CRAS-2 has validated that the early post-traumatic administration of the tranexamic acid, within 8 hours after the injury, in adult patients with traumas or in patients with the risk of significant haemorrhage, reduces the fatality rate.
The tranexamic acid is a synthetic derivative of lysine, an amino acid which blocks lysine binding sites of the plasminogen molecule which are essential for its biding to fibrin. This mechanism inhibits the plasminogen activation via a plasminogen activator which also binds to fibrin. Thus, it prevents the conversion of plasminogen into plasmin, which is essential for fibrin dissolution, the integral element of a stable clot. The second important antifibrinolytic effect is blocking the lysine binding sites on the free plasmin molecule which has already been formed through the conversion from the plasminogen. This inhibits its binding to fibrin, and the TRAXA-plasmin complex is rapidly inactivated with the α-2-antiplasmin and α-2-macroglobulin. Biological half-life is approximately 2-3 hours.
A trauma in the organism triggers the immunologic response. The initial immunologic reaction occurs at the location of the injury, and it is called an inflammation. The inflammatory response is characterized by a complex interaction of macrophages (a type of leukocytes which develop from monocytes and are a part of the mononuclear phagocyte system, the main task of which are phagocytosis, i.e. the clearance of foreign materiel from the organism, performing the immunologic function - the defence against foreign materiel - antigens, and the regulation of the inflammation via interleukins which they secrete - IL1, IL-2,TNF) and dendritic cells (antigen-presenting cells), the consequence of which is the release of cytokines (interleukins - glycoproteins which regulate interactions among cells) and chemokine (small proteins from the cytokine group - able to induce chemotaxis, cell migration), and the activation of the neutrophils, monocytes and mesenchymal stem cells (cells not containing any information, located in the adipose tissue, cartilage and muscle tissue).
If the initial inflammatory response at the location of the injury is strong enough, it will develop into a systemic inflammatory response, called systemic inflammatory response syndrome (SIRS), which implies an inflammatory response of the entire body without a proven source of infection. The criteria for the diagnosis of the SIRS are: heart rate higher than 90 bpm; body temperature lower than 36°C or higher than 38°C; tachypnoea, respiratory rate higher than 20 breaths per minute or the partial pressure of carbon dioxide in the blood lower than 4.3 kPa (32 mm Hg); the number of white blood cells, leukocytes, lower than 4.000 cells in 1 mm³ or higher than 12.000 cells in 1 mm³; or the presence of more than 10% of immature neutrophils. A destructive immunologic inflammatory cascade can prevent or delay healing.
At the same time the compensatory anti-inflammatory response syndrome (CARS) is initiated, which includes the immunologic response with the aim of re-establishing the immunologic homeostasis. It is characterized by: a reduced cytokine response of monocytes to the stimulation; a reduced number of antigen-presenting receptors (human leukocyte antigens or HLA) on monocytes; an increased level of IL-10, an anti-inflammatory cytokine; lymphocyte apoptosis (T-cells); lymphocyte dysfunction, i.e. reduced proliferation; reduced Th1 proinflammatory cytokine production (a shift in homoeostasis towards the Th2 phenotype facilitated by the regulatory T lymphocytes). It clinically manifests as skin allergy, hypothermia and leukopenia. Additional criteria include elevated levels of C-reactive proteins, lactates and hyperglycaemia. If the immunosuppressive response persists, it may increase the possibility of an infection occurring, and the inability to defend against the infection, which may result in the development of sepsis, multiple organ failure and death.
Due to the wide clinical and laboratory criteria which both the SIRS and CARS terms include, they are not the best terms for describing the immunologic response to a trauma, and a new term has been introduced - the post-traumatic immunosuppression (PTI), characterised by: a change on the immunologic cells (neutrophilia, monocytosis, increased number of mesenchymal stromal cells, reduced expression of HLA-DR on monocytes, reduced function of natural killer (NK) cells, increased lymphocyte apoptosis, a shift in homoeostasis towards the Th2 phenotype facilitated by Treg lymphocytes - CD4+CD25+CD127-); a change in production levels of various cytokines (anti-inflammatory cytokines): IL-10, IL-4; anti- and pro-inflammatory cytokine: IL-6; pro-inflammatory cytokines IL-2, TNF-α, IFN-γ); the activation of the complement system (C5a and C3a via factor VII - tissue factor system, activated by cell damage).
Post-traumatic immunosuppression can be made worse by transfusion, haemorrhage, stress, significant surgical operation and immunosuppressive drugs.
The research has shown that Treg lymphocytes CD4+CD25+CD127- have an important role in controlling the acquired and innate immunity (comprising 6-8% of all CD4+ lymphocytes).
The normal function of Treg lymphocytes is the suppression of the T-cell response against its own antigens.
Stopping haemorrhage prevents the occurrence of anaemia, as well as the need for transfusion of blood products, which lead to developing the post-traumatic immunosuppression (PTI).
Monitoring the immunologic status of patients with the understanding of the PTI mechanism can enable timely and individual modulation of the immunologic status with pre-planned procedures (preventing haemorrhage, anaemia, avoiding transfusion) and/or immunotherapy (drugs and nutrients), and thereby prevent the occurrence of complications, such as infections. Infections may result in sepsis and multiple-organ failure, and eventually be lethal for the patient.
The research has proved that Treg lymphocytes CD4+CD25+CD127- have an important role in controlling the acquired and innate immunity (comprising 6-8% of all CD4+ lymphocytes).
The normal function of Treg lymphocytes is the suppression of the T-cell response against its own antigens.
There are two main types of regulatory lymphocytes: natural Treg, which are mostly developed in the thymus, and inducible Treg, which arise in the periphery after being exposed to cytokines, antigen-presenting cells or immunosuppressive drugs. It may be difficult to differentiate these two lymphocyte Treg populations in vivo. Nevertheless, it is known that different stages of the infection require different regulations. Acute infection, tissue damage, inflammation caused by the innate immunologic response is limited, i.e. locally controlled via natural Treg lymphocytes. This mechanism triggers the activation of inducible Treg lymphocytes.
For the first time, in 1995, it was described that the suppression of CD4+ T-lymphocytes is caused by a low T-cell population with the CD4+ CD25+ expression. Natural Treg lymphocytes, apart from belonging to CD4+ T-cell population, have a CD25+ receptor, an α-receptor chain for IL-2, and a receptor for the cytotoxic T-lymphocytic antigen 4 (CTLA 4), the tumour necrosis factor receptor (TNF), but it differs from the activated T-cells by the expression of the transcription factor FoxP3 (transcription factor encoded with the FoxP3 gene). The expression of CD 127lo, an α-chain receptor for the interleukin 7 enables us to differentiate Treg lymphocytes from the activated T-lymphocytes via flow cytometry. The number of CD25+CD127lo cells correlates to the number of CD25+FoxP3+ cells in the peripheral blood.
Different studies show that the application of the 3-colour flow cytometry shows small variation in the percentage of Treg lymphocytes in the peripheral blood from 6.35% to 8.34%.
There is a number of different mechanisms which achieve regulation by using the Treg lymphocytes: the long-term interaction with dendritic cells (DC), thereby modulating the function of antigen-presenting cells (APC), the production of the anti-inflammatory cytokine, IL-10 and the CTLA4 expression on Treg cells which induces the enzyme indoleamine 2,3-dioxygenase (IDO) in APC which degrade the amino acid tryptophan, the lack of which inhibits the activation of T-cells and induces T-cell apoptosis. Treg lymphocytes also induce the apoptosis of monocytes and affect the lower expression of HLA-DR on monocytes whereby they directly affect the innate immunological response.
Elevated, suppressive activity of Treg cells in traumas prevents the protective Th1 response for up to 7 days in comparison with the healthy population.
A pharmacokinetic study has shown that peak fibrinolytic activity is present for 6 hours after the incision and it persists for 18 hours in total knee and hip arthroplasty. The administration of the tranexamic acid in optional orthopaedic surgery of total hip (THA) and knee (TKA) arthroplasty reduces the postoperative haemorrhage, as well as the number and volume of the postoperative autologous blood.
A randomized, placebo-controlled trial CRAS-2 has validated that the early post-traumatic administration of the tranexamic acid, within 8 hours after the injury, in adult patients with traumas or in patients with the risk of significant haemorrhage, reduces the fatality rate.
The tranexamic acid is a synthetic derivative of lysine, an amino acid which blocks lysine binding sites of the plasminogen molecule which are essential for its biding to fibrin. This mechanism inhibits the plasminogen activation via a plasminogen activator which also binds to fibrin. Thus, it prevents the conversion of plasminogen into plasmin, which is essential for fibrin dissolution, the integral element of a stable clot. The second important antifibrinolytic effect is blocking the lysine binding sites on the free plasmin molecule which has already been formed through the conversion from the plasminogen. This inhibits its binding to fibrin, and the TRAXA-plasmin complex is rapidly inactivated with the α-2-antiplasmin and α-2-macroglobulin. Biological half-life is approximately 2-3 hours.
A trauma in the organism triggers the immunologic response. The initial immunologic reaction occurs at the location of the injury, and it is called an inflammation. The inflammatory response is characterized by a complex interaction of macrophages (a type of leukocytes which develop from monocytes and are a part of the mononuclear phagocyte system, the main task of which are phagocytosis, i.e. the clearance of foreign materiel from the organism, performing the immunologic function - the defence against foreign materiel - antigens, and the regulation of the inflammation via interleukins which they secrete - IL1, IL-2,TNF) and dendritic cells (antigen-presenting cells), the consequence of which is the release of cytokines (interleukins - glycoproteins which regulate interactions among cells) and chemokine (small proteins from the cytokine group - able to induce chemotaxis, cell migration), and the activation of the neutrophils, monocytes and mesenchymal stem cells (cells not containing any information, located in the adipose tissue, cartilage and muscle tissue).
If the initial inflammatory response at the location of the injury is strong enough, it will develop into a systemic inflammatory response, called systemic inflammatory response syndrome (SIRS), which implies an inflammatory response of the entire body without a proven source of infection. The criteria for the diagnosis of the SIRS are: heart rate higher than 90 bpm; body temperature lower than 36°C or higher than 38°C; tachypnoea, respiratory rate higher than 20 breaths per minute or the partial pressure of carbon dioxide in the blood lower than 4.3 kPa (32 mm Hg); the number of white blood cells, leukocytes, lower than 4.000 cells in 1 mm³ or higher than 12.000 cells in 1 mm³; or the presence of more than 10% of immature neutrophils. A destructive immunologic inflammatory cascade can prevent or delay healing.
At the same time the compensatory anti-inflammatory response syndrome (CARS) is initiated, which includes the immunologic response with the aim of re-establishing the immunologic homeostasis. It is characterized by: a reduced cytokine response of monocytes to the stimulation; a reduced number of antigen-presenting receptors (human leukocyte antigens or HLA) on monocytes; an increased level of IL-10, an anti-inflammatory cytokine; lymphocyte apoptosis (T-cells); lymphocyte dysfunction, i.e. reduced proliferation; reduced Th1 proinflammatory cytokine production (a shift in homoeostasis towards the Th2 phenotype facilitated by the regulatory T lymphocytes). It clinically manifests as skin allergy, hypothermia and leukopenia. Additional criteria include elevated levels of C-reactive proteins, lactates and hyperglycaemia. If the immunosuppressive response persists, it may increase the possibility of an infection occurring, and the inability to defend against the infection, which may result in the development of sepsis, multiple organ failure and death.
Due to the wide clinical and laboratory criteria which both the SIRS and CARS terms include, they are not the best terms for describing the immunologic response to a trauma, and a new term has been introduced - the post-traumatic immunosuppression (PTI), characterised by: a change on the immunologic cells (neutrophilia, monocytosis, increased number of mesenchymal stromal cells, reduced expression of HLA-DR on monocytes, reduced function of natural killer (NK) cells, increased lymphocyte apoptosis, a shift in homoeostasis towards the Th2 phenotype facilitated by Treg lymphocytes - CD4+CD25+CD127-); a change in production levels of various cytokines (anti-inflammatory cytokines): IL-10, IL-4; anti- and pro-inflammatory cytokine: IL-6; pro-inflammatory cytokines IL-2, TNF-α, IFN-γ); the activation of the complement system (C5a and C3a via factor VII - tissue factor system, activated by cell damage).
Post-traumatic immunosuppression can be made worse by transfusion, haemorrhage, stress, significant surgical operation and immunosuppressive drugs.
The research has shown that Treg lymphocytes CD4+CD25+CD127- have an important role in controlling the acquired and innate immunity (comprising 6-8% of all CD4+ lymphocytes).
The normal function of Treg lymphocytes is the suppression of the T-cell response against its own antigens.
Stopping haemorrhage prevents the occurrence of anaemia, as well as the need for transfusion of blood products, which lead to developing the post-traumatic immunosuppression (PTI).
Monitoring the immunologic status of patients with the understanding of the PTI mechanism can enable timely and individual modulation of the immunologic status with pre-planned procedures (preventing haemorrhage, anaemia, avoiding transfusion) and/or immunotherapy (drugs and nutrients), and thereby prevent the occurrence of complications, such as infections. Infections may result in sepsis and multiple-organ failure, and eventually be lethal for the patient.
The research has proved that Treg lymphocytes CD4+CD25+CD127- have an important role in controlling the acquired and innate immunity (comprising 6-8% of all CD4+ lymphocytes).
The normal function of Treg lymphocytes is the suppression of the T-cell response against its own antigens.
There are two main types of regulatory lymphocytes: natural Treg, which are mostly developed in the thymus, and inducible Treg, which arise in the periphery after being exposed to cytokines, antigen-presenting cells or immunosuppressive drugs. It may be difficult to differentiate these two lymphocyte Treg populations in vivo. Nevertheless, it is known that different stages of the infection require different regulations. Acute infection, tissue damage, inflammation caused by the innate immunologic response is limited, i.e. locally controlled via natural Treg lymphocytes. This mechanism triggers the activation of inducible Treg lymphocytes.
For the first time, in 1995, it was described that the suppression of CD4+ T-lymphocytes is caused by a low T-cell population with the CD4+ CD25+ expression. Natural Treg lymphocytes, apart from belonging to CD4+ T-cell population, have a CD25+ receptor, an α-receptor chain for IL-2, and a receptor for the cytotoxic T-lymphocytic antigen 4 (CTLA 4), the tumour necrosis factor receptor (TNF), but it differs from the activated T-cells by the expression of the transcription factor FoxP3 (transcription factor encoded with the FoxP3 gene). The expression of CD 127lo, an α-chain receptor for the interleukin 7 enables us to differentiate Treg lymphocytes from the activated T-lymphocytes via flow cytometry. The number of CD25+CD127lo cells correlates to the number of CD25+FoxP3+ cells in the peripheral blood.
Different studies show that the application of the 3-colour flow cytometry shows small variation in the percentage of Treg lymphocytes in the peripheral blood from 6.35% to 8.34%.
There is a number of different mechanisms which achieve regulation by using the Treg lymphocytes: the long-term interaction with dendritic cells (DC), thereby modulating the function of antigen-presenting cells (APC), the production of the anti-inflammatory cytokine, IL-10 and the CTLA4 expression on Treg cells which induces the enzyme indoleamine 2,3-dioxygenase (IDO) in APC which degrade the amino acid tryptophan, the lack of which inhibits the activation of T-cells and induces T-cell apoptosis. Treg lymphocytes also induce the apoptosis of monocytes and affect the lower expression of HLA-DR on monocytes whereby they directly affect the innate immunological response.
Elevated, suppressive activity of Treg cells in traumas prevents the protective Th1 response for up to 7 days in comparison with the healthy population.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hemorrhage
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
SINGLE
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
The control group (Group K)
The control group (Group K) is comprised of surgical patients who will not receive blood transfusion, and who have contraindications for Tranexamic Acid.
Group Type
NO_INTERVENTION
No interventions assigned to this group
Group A, Tranexamic acid
The treatment group (Group A) is comprised of the patients who will receive Tranexamic acid 1g intravenous 15 min. before releasing the pneumatic tourniquet and the repeating dose 3 hours later
Group Type
ACTIVE_COMPARATOR
Tranexamic Acid
Intervention Type
DRUG
Imunomodulatory effect
Group B, autologous transfusion
The treatment group (Group B) will be comprised of the patients who in the second selection have one or more contraindications for Tranexamic Acid administration and transfusion of autologous blood will be performed.
Group Type
OTHER
Tranexamic Acid
Intervention Type
DRUG
Imunomodulatory effect
Group C, alogenous transfusion
The treatment group (Group C) contraindications for Tranexamic Acid administration and the transfusion of alogenous blood will be performed in the case of acute haemorrhage followed by patient's hemodynamic instability.
Group Type
OTHER
Tranexamic Acid
Intervention Type
DRUG
Imunomodulatory effect
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tranexamic Acid
Imunomodulatory effect
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Medsamic
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ASA I/II status
* scheduled for endoprosthetic total knee arthroplasty.
* laboratory results suitable for elective endoprosthetic surgery: blood panel, coagulation, liver enzymes, kidney function parameters, urine sediment;
* patient voluntarily, in accordance with the KBCSM form on the administration of Tranexamic Acid in endoprosthetic total knee arthroplasty, give their consent for its administration.
* signed informed consent for transfusion
* scheduled for endoprosthetic total knee arthroplasty.
* laboratory results suitable for elective endoprosthetic surgery: blood panel, coagulation, liver enzymes, kidney function parameters, urine sediment;
* patient voluntarily, in accordance with the KBCSM form on the administration of Tranexamic Acid in endoprosthetic total knee arthroplasty, give their consent for its administration.
* signed informed consent for transfusion
Exclusion Criteria
* general anaesthesia
* revision arthroplasty
* previous blood transfusions
* known allergic reaction to TRAXA
* presence of an infection and/or acutization of a chronic disease
* existing malignant disease
* autoimmune disease
* hematologic disease
* diabetes
* renal failure
* liver cirrhosis
* chronic anticoagulant therapy
* analgesia by non-steroidal anti-inflammatory drugs
* combined use of the autologous and allogeneic blood postoperatively when the recovery of the autologous blood is insufficient in relation to the haemorrhage.
* known risk of thrombosis or thromboembolic events (thrombogenic valve disease, thrombogenic rhythm disorder, coagulation-hypercoagulation disorder)
* epilepsy
* patients who use oral contraceptives
* known retinal arterial or venous occlusions.
To patients who fulfil the participation criteria for the trial in the first selection, and for whom TRAXA is contraindicated in the second selection, blood transfusion will be administered in accordance with the indication.
* revision arthroplasty
* previous blood transfusions
* known allergic reaction to TRAXA
* presence of an infection and/or acutization of a chronic disease
* existing malignant disease
* autoimmune disease
* hematologic disease
* diabetes
* renal failure
* liver cirrhosis
* chronic anticoagulant therapy
* analgesia by non-steroidal anti-inflammatory drugs
* combined use of the autologous and allogeneic blood postoperatively when the recovery of the autologous blood is insufficient in relation to the haemorrhage.
* known risk of thrombosis or thromboembolic events (thrombogenic valve disease, thrombogenic rhythm disorder, coagulation-hypercoagulation disorder)
* epilepsy
* patients who use oral contraceptives
* known retinal arterial or venous occlusions.
To patients who fulfil the participation criteria for the trial in the first selection, and for whom TRAXA is contraindicated in the second selection, blood transfusion will be administered in accordance with the indication.
Minimum Eligible Age
30 Years
Maximum Eligible Age
80 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clinical Hospital Centre Zagreb
OTHER
Sponsor Role
collaborator
Sisters of Mercy University Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Renata Letica-Brnadić
Principal Investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Renata Letica-Brnadić
Role: STUDY_CHAIR
Clinical Hospital Centre "Sisters of Mercy"
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Klinički Bolnički Centar Sestre Milosrdnice
Zagreb, , Croatia
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Croatia
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, McClelland B, Laupacis A, Fergusson D. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD001886. doi: 10.1002/14651858.CD001886.pub2.
Reference Type
BACKGROUND
Astedt B. Clinical pharmacology of tranexamic acid. Scand J Gastroenterol Suppl. 1987;137:22-5.
Reference Type
BACKGROUND
Roberts I, Shakur H, Coats T, Hunt B, Balogun E, Barnetson L, Cook L, Kawahara T, Perel P, Prieto-Merino D, Ramos M, Cairns J, Guerriero C. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess. 2013 Mar;17(10):1-79. doi: 10.3310/hta17100.
Reference Type
BACKGROUND
Oremus K, Sostaric S, Trkulja V, Haspl M. Influence of tranexamic acid on postoperative autologous blood retransfusion in primary total hip and knee arthroplasty: a randomized controlled trial. Transfusion. 2014 Jan;54(1):31-41. doi: 10.1111/trf.12224. Epub 2013 Apr 25.
Reference Type
BACKGROUND
Raveendran R, Wong J. Tranexamic acid: more evidence for its use in joint replacement surgery. Transfusion. 2014 Jan;54(1):2-3. doi: 10.1111/trf.12494. No abstract available.
Reference Type
BACKGROUND
Parkin J, Cohen B. An overview of the immune system. Lancet. 2001 Jun 2;357(9270):1777-89. doi: 10.1016/S0140-6736(00)04904-7.
Reference Type
BACKGROUND
Islam MN, Bradley BA, Ceredig R. Sterile post-traumatic immunosuppression. Clin Transl Immunology. 2016 Apr 29;5(4):e77. doi: 10.1038/cti.2016.13. eCollection 2016 Apr.
Reference Type
BACKGROUND
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992 Jun;101(6):1644-55. doi: 10.1378/chest.101.6.1644.
Reference Type
BACKGROUND
Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med. 1996 Oct 15;125(8):680-7. doi: 10.7326/0003-4819-125-8-199610150-00009.
Reference Type
BACKGROUND
Ward NS, Casserly B, Ayala A. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med. 2008 Dec;29(4):617-25, viii. doi: 10.1016/j.ccm.2008.06.010.
Reference Type
BACKGROUND
Osuka A, Ogura H, Ueyama M, Shimazu T, Lederer JA. Immune response to traumatic injury: harmony and discordance of immune system homeostasis. Acute Med Surg. 2014 Jan 28;1(2):63-69. doi: 10.1002/ams2.17. eCollection 2014 Apr.
Reference Type
BACKGROUND
Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A, Fazekas de St Groth B. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med. 2006 Jul 10;203(7):1693-700. doi: 10.1084/jem.20060468. Epub 2006 Jul 3.
Reference Type
BACKGROUND
Venet F, Chung CS, Kherouf H, Geeraert A, Malcus C, Poitevin F, Bohe J, Lepape A, Ayala A, Monneret G. Increased circulating regulatory T cells (CD4(+)CD25 (+)CD127 (-)) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med. 2009 Apr;35(4):678-86. doi: 10.1007/s00134-008-1337-8. Epub 2008 Oct 23.
Reference Type
BACKGROUND
Venet F, Chung CS, Monneret G, Huang X, Horner B, Garber M, Ayala A. Regulatory T cell populations in sepsis and trauma. J Leukoc Biol. 2008 Mar;83(3):523-35. doi: 10.1189/jlb.0607371. Epub 2007 Oct 3.
Reference Type
BACKGROUND
Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol. 2007 Nov;7(11):875-88. doi: 10.1038/nri2189.
Reference Type
BACKGROUND
Shevach EM, DiPaolo RA, Andersson J, Zhao DM, Stephens GL, Thornton AM. The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol Rev. 2006 Aug;212:60-73. doi: 10.1111/j.0105-2896.2006.00415.x.
Reference Type
BACKGROUND
Hartigan-O'Connor DJ, Poon C, Sinclair E, McCune JM. Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Methods. 2007 Jan 30;319(1-2):41-52. doi: 10.1016/j.jim.2006.10.008. Epub 2006 Nov 3.
Reference Type
BACKGROUND
Fragkou PC, Torrance HD, Pearse RM, Ackland GL, Prowle JR, Owen HC, Hinds CJ, O'Dwyer MJ. Perioperative blood transfusion is associated with a gene transcription profile characteristic of immunosuppression: a prospective cohort study. Crit Care. 2014 Oct 1;18(5):541. doi: 10.1186/s13054-014-0541-x.
Reference Type
BACKGROUND
Blanie A, Bellamy L, Rhayem Y, Flaujac C, Samama CM, Fontenay M, Rosencher N. Duration of postoperative fibrinolysis after total hip or knee replacement: a laboratory follow-up study. Thromb Res. 2013 Jan;131(1):e6-e11. doi: 10.1016/j.thromres.2012.11.006. Epub 2012 Nov 26.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EP-12939/18-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty
NCT01370460
COMPLETED
PHASE2
Use of Tranexamic Acid in the Total Knee Arthroplasty.
NCT05919615
COMPLETED
NA
Tranexamic Acid for Total Knee Arthroscopy
NCT04443920
COMPLETED
PHASE4
Tranexamic Acid in Knee Joint Surgery
NCT02278263
COMPLETED
PHASE4
Efficacy Comparison of Topical and Intravenous Tranexamic Acid to Reduce the Number of Blood Transfusions in TKA
NCT01881568
COMPLETED
PHASE3
The Efficacy and Safety of Using Tranexamic Acid by Different Means to Reduce Blood Loss During Total Knee Replacement
NCT02117128
COMPLETED
PHASE4
Prospective Investigation of Intra-Articular Tranexamic Acid Use in Elective Hip Arthroplasty
NCT06903299
RECRUITING
Efficacy of Intra-auricular Tranexamic Acid in Total Knee Arthroplasty
NCT04085575
COMPLETED
PHASE4
Postoperative Drainage in Total Knee Arthroplasty in the Presence of Tranexamic Acid
NCT03915756
UNKNOWN
NA
Effect of Suction Drains in Total Knee Arthroplasty With Tranexamic Acid
NCT03145493
COMPLETED
NA
Tranexamic Acid and Blood Clots in Knee Surgery
NCT02867163
COMPLETED
Single Versus Multi-Dose Oral Tranexamic Acid in Patients at High Risk for Blood Transfusion After Total Joint Arthroplasty
NCT02926651
WITHDRAWN
PHASE4
Investigating the Effect of Intravenous and Oral Tranexamic Acid on Blood Loss After Primary Hip and Knee Arthroplasty
NCT03690037
COMPLETED
PHASE4
Serial Use of Intravenous and Oral Tranexamic Acid in Primary Total Knee Arthroplasty Patients
NCT03109652
UNKNOWN
PHASE4
Tranexamic Acid Use on Pain, Mobility and Bleeding Following Total Hip and Total Knee Arthroplasty
NCT06208267
RECRUITING
NA
Tranexamic Acid in Major Vascular Surgery
NCT02335359
COMPLETED
PHASE4
Topical Tranexamic Acid for Total Knee Arthroplasty
NCT00985920
COMPLETED
PHASE4
The Aim of This Study is to Examine the Effect of Intravenously Administered Tranexamic Acid (TXA) on the Visual Clarity, Perioperative Hemorrhage, Duration and Early Postoperative Course of Shoulder Arthroscopy in Beach Chair Position.
NCT05397652
COMPLETED
PHASE4
Alteration of Thrombelastography and Coagulation Function in Patients Undergoing Total Knee Arthroplasty With Intra-articular Tranexamic Acid Administration
NCT05490160
UNKNOWN
The Efficacy and Safety of Using Tranexamic Acid to Reduce Blood Loss In Simultaneous Bilateral Total Knee Arthroplasty
NCT02504125
COMPLETED
PHASE4
Tranexamic Acid Dosing for Total Joint Arthroplasty
NCT02584725
COMPLETED
PHASE4
Thromboelastogram During Total Knee Replacement
NCT02373969
COMPLETED
Effect of Topical and Intravenous Tranexamic Acid (TXA) on Thrombogenic Markers in Patients Undergoing Knee Replacement
NCT02540226
COMPLETED
PHASE4
Evaluation of the Pharmacokinetic Profile of Tranexamic Acid, After Injection in a Knee Neo-articulation.
NCT02319915
COMPLETED
EARLY_PHASE1